Idexx Laboratories (IDXX) fundamentals: P/E, valuation, undervalued?
Idexx Laboratories · Health Care · ref. ETF XLV · price $545.08
In short — Idexx Laboratories trades at 38.9× earnings (P/E), 32.6× forward, with a net margin of 25.0 % and revenue growth of +10 %. Read: Fairly valued (P/E 33 in line with ~18% growth (PEG 1.9)).
Is Idexx Laboratories stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$545.08-15.8% over range
Aug 28, 25low $526.44 · high $766.68Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
50% recommend buying · 4 analysts
Valuation : Fairly valued — P/E 33 in line with ~18% growth (PEG 1.9)
Valuation
38.9
P/E (price/earnings)
32.6
Forward P/E
2.21
PEG
26.7
Price/book (P/B)
$42.9B
Market cap
14.01
EPS
Profitability & growth
25.0 %
Net margin
+10 %
Revenue growth
+18 %
Earnings growth
$1.1B
Total debt
Idexx Laboratories income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $3.4B | $679M | 20.2 % |
| 2023 | $3.7B | $845M | 23.1 % |
| 2024 | $3.9B | $888M | 22.8 % |
| 2025 | $4.3B | $1.1B | 24.6 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Idexx Laboratories's P/E and is the stock undervalued? What's a good P/E?
Idexx Laboratories's P/E is 38.9 (forward 32.6). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Fairly valued".
Is Idexx Laboratories profitable?
Idexx Laboratories has a net margin of 25.0 % (EPS 14.01). The company is profitable.
Is IDXX stock expensive?
Our read: "Fairly valued" — P/E 33 in line with ~18% growth (PEG 1.9). Cross-check with growth and sector.
💬 A question about Idexx Laboratories? The JPI assistant answers using our backtest data.
Keep exploring Idexx Laboratories